WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinionOlezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in processOn track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif., Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024."Today, we stand on the cusp of a new era for Ionis, with our first co-comme ...

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth.I have been considering Ionis (NASDAQ: IONS ) as a potential "strong buy" opportunity for some time. I covered the Carlsbad, California-based developer of antisense, oligonucleotide therapeutics on multiple occasions, most recently in May, short ...

Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern TimeCARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc.Fo ...

Core Insights - Ionis Pharmaceuticals announced new three-year data from the Phase 2 open-label extension study and pivotal Phase 3 studies of donidalorsen, demonstrating its potential to significantly reduce hereditary angioedema (HAE) attacks with sustained effects over time [1][2] Group 1: Donidalorsen Efficacy - Donidalorsen has shown significant reductions in HAE attacks, leading to high levels of disease control and clinically meaningful improvements in quality of life for a vast majority of patients, sustained for up to three years [2] - The presentations at the 2024 ACAAI Annual Scientific Meeting will cover various aspects of donidalorsen, including patient-reported outcomes and safety and efficacy after switching to donidalorsen [2] Group 2: Background on HAE - Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent severe swelling attacks, affecting over 20,000 patients in the U.S. and Europe [3] - Prophylactic treatment approaches are commonly used by doctors in the U.S. to prevent and reduce the severity of HAE attacks [3] Group 3: About Donidalorsen - Donidalorsen is an investigational RNA-targeted medicine aimed at reducing prekallikrein (PKK) production, which is crucial in activating inflammatory mediators associated with HAE attacks [4] - If approved, donidalorsen could serve as an effective prophylactic treatment for HAE [4] Group 4: Company Overview - Ionis Pharmaceuticals has been innovating medicines for serious diseases for three decades, with a leading pipeline in neurology, cardiology, and other high-need areas [5] - The company is recognized as a pioneer in RNA-targeted medicines and continues to advance new approaches in gene editing [5]

Ionis Pharmaceuticals (IONS) announced that it is floating a secondary issue of 11.5 million shares of its common stock to the public at an issue price of $43.50 per share, amounting to nearly $500.3 million. The company also granted an option to underwriters of the issue to purchase an additional 1.725 million shares at the same price. The secondary offering is expected to close today. Buy Why Did IONS Stock Fall? Ionis' shares fell more than 12% on Tuesday after the announcement. Though the issue does not ...

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share. The aggregate gross proceeds to Ionis from this offering are expected to be approximately $500.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ionis. Ionis ha ...

Core Viewpoint - Ionis Pharmaceuticals, Inc. announced a proposed underwritten public offering of $500 million of its common stock, with an option for underwriters to purchase an additional $75 million [1] Group 1: Offering Details - The net proceeds from the offering will be used to fund independent commercial launches, late-stage clinical programs, earlier pipeline programs, research and development activities, as well as for working capital and general corporate purposes [1] - The offering is subject to market and other conditions, with no assurance on the completion, size, or terms of the offering [1] - Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering [2] Group 2: Regulatory Information - A shelf registration statement for the offered securities was filed with the SEC on November 24, 2023, and became effective upon filing [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC on September 9, 2024, and will be available for free on the SEC's website [3] Group 3: Company Background - Ionis Pharmaceuticals has been innovating medicines for serious diseases for three decades, currently marketing five medicines and maintaining a leading pipeline in neurology, cardiology, and other high-need areas [5] - The company is a pioneer in RNA-targeted medicines and continues to drive innovation in RNA therapies and gene editing [5]

California-based Ionis Pharmaceuticals (IONS) is focused on the discovery and development of RNA-targeted therapies using its proprietary platform for itself and its partners. It uses this technology to generate a broad pipeline of medicines, targeting neurological, cardiovascular and specialty rare diseases. Despite marketing no wholly-owned drug in its portfolio, IONS enjoys a diverse stream of revenues, including commercial products and royalties and numerous sources of collaborative and R&D revenues. Th ...

kemalbas Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a biopharmaceutical company specializing in RNA-targeted therapies. It uses antisense DNA technology to design drugs that regulate the production of specific proteins to treat neurological and cardiometabolic diseases, directly addressing their root causes. The company presents an extensive pipeline with partnered and in-house drug developments to address several conditions. It also collaborates with major pharmaceutical companies like Biogen (BIIB), Ast ...

Ionis Pharmaceuticals (IONS) incurred a loss of 45 cents per share for second-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of 95 cents per share. Earnings include compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 24 cents against a loss of 40 cents per share in the year-ago quarter. Total revenues were $225 million in the second quarter, which beat the Zacks Consensus Estimate of $147.0 million. Revenues rose 20% year o ...